Premium
Serum zinc levels in lung cancer patients
Author(s) -
Issell Brian F.,
Macfadyen Bruce V.,
Gum Elizabeth T.,
Valdivieso Manuel,
Dudrick Stanley J.,
Bodey Gerald P.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810401)47:7<1845::aid-cncr2820470721>3.0.co;2-b
Subject(s) - zinc , medicine , lung cancer , microgram , chemotherapy , cancer , gastroenterology , serum concentration , lung , endocrinology , immunology , biology , biochemistry , chemistry , organic chemistry , in vitro
Serum zinc concentrations were determined in 26 extensive squamous cell lung cancer patients and were tested for correlations with survival, response to therapy, nutritional status indices, and various host defense characteristics. Subnormal serum zinc levels were found in 24 of the 26 patients. The mean serum zinc concentration was 43.2/ μg 100 ml ± 3.6 S.E.M. (normal = 80–100 μg/100 ml). A significant ( P = 0.007) survival advantage was demonstrated for those patients with pretreatment zinc concentrations > 45 μg%, but serum zinc levels did not correlate with response to chemotherapy (also significantly affecting survival). Decreased serum zinc concentrations were significantly associated with decreased neutrophil migration measured by the skin window technique and with decreased triceps skin fold thickness but not with any of the other host defense and nutritional indices measured. These data suggest that further studies are indicated to examine the role of serum zinc concentration as a possible sensitive prognostic characteristic and to determine if zinc administration may be of therapeutic benefit in cancer patients.